Teachers Retirement System of The State of Kentucky decreased its position in shares of Coherus Biosciences Inc (NASDAQ:CHRS) by 4.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 189,045 shares of the biotechnology company’s stock after selling 8,500 shares during the period. Teachers Retirement System of The State of Kentucky owned about 0.28% of Coherus Biosciences worth $3,119,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds and other institutional investors have also recently bought and sold shares of CHRS. Principal Financial Group Inc. bought a new position in Coherus Biosciences in the 1st quarter valued at approximately $115,000. Tower Research Capital LLC TRC bought a new position in Coherus Biosciences in the 2nd quarter valued at approximately $118,000. Dynamic Technology Lab Private Ltd bought a new position in Coherus Biosciences in the 2nd quarter valued at approximately $193,000. BlueMountain Capital Management LLC bought a new position in Coherus Biosciences in the 2nd quarter valued at approximately $214,000. Finally, Fox Run Management L.L.C. bought a new position in Coherus Biosciences in the 2nd quarter valued at approximately $266,000. Institutional investors and hedge funds own 91.19% of the company’s stock.
CHRS has been the subject of several research reports. Zacks Investment Research downgraded shares of Coherus Biosciences from a “hold” rating to a “sell” rating in a research note on Monday, August 13th. BidaskClub downgraded shares of Coherus Biosciences from a “hold” rating to a “sell” rating in a research note on Wednesday, September 19th. Maxim Group reissued a “buy” rating and issued a $25.00 price objective on shares of Coherus Biosciences in a research note on Tuesday, September 25th. HC Wainwright initiated coverage on shares of Coherus Biosciences in a research note on Tuesday, August 28th. They issued a “buy” rating and a $28.00 price objective for the company. Finally, Cowen reissued a “buy” rating and issued a $45.00 price objective on shares of Coherus Biosciences in a research note on Friday, November 2nd. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the stock. Coherus Biosciences currently has a consensus rating of “Hold” and a consensus price target of $27.20.
CHRS stock opened at $12.16 on Friday. The firm has a market cap of $827.18 million, a PE ratio of -2.71 and a beta of 3.72. Coherus Biosciences Inc has a 52-week low of $8.20 and a 52-week high of $20.66. The company has a quick ratio of 5.31, a current ratio of 5.31 and a debt-to-equity ratio of 8.29.
Coherus Biosciences (NASDAQ:CHRS) last released its quarterly earnings results on Thursday, November 8th. The biotechnology company reported ($0.87) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.79) by ($0.08). On average, research analysts predict that Coherus Biosciences Inc will post -3.12 EPS for the current year.
TRADEMARK VIOLATION WARNING: “Teachers Retirement System of The State of Kentucky Has $3.12 Million Position in Coherus Biosciences Inc (CHRS)” was originally reported by WKRB News and is the property of of WKRB News. If you are reading this story on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at https://www.wkrb13.com/2018/11/23/teachers-retirement-system-of-the-state-of-kentucky-has-3-12-million-position-in-coherus-biosciences-inc-chrs.html.
About Coherus Biosciences
Coherus BioSciences, Inc, a biosimilar company, develops and commercializes various therapeutic products worldwide. The company engages in the development of late-stage clinical products, including CHS-1701 pegfilgrastim biosimilar, a granulocyte colony-stimulating factor product candidate; CHS-1420 adalimumab biosimilar, an anti-tumor necrosis factor product candidate; and CHS-0214, an etanercept biosimilar for rheumatoid arthritis and psoriasis.
Further Reading: How mutual funds make money
Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.